Adimmune Corporation

TWSE:4142 Stock Report

Market Cap: NT$7.0b

Adimmune Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Steve Chan

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure18yrs
CEO ownershipn/a
Management average tenure10.9yrs
Board average tenure9.1yrs

Recent management updates

Recent updates

Analysis Article • Jan 13

There's No Escaping Adimmune Corporation's (TWSE:4142) Muted Revenues Despite A 26% Share Price Rise

Adimmune Corporation ( TWSE:4142 ) shareholders are no doubt pleased to see that the share price has bounced 26% in the...
Analysis Article • Aug 13

Little Excitement Around Adimmune Corporation's (TWSE:4142) Revenues

You may think that with a price-to-sales (or "P/S") ratio of 7.2x Adimmune Corporation ( TWSE:4142 ) is definitely a...
Analysis Article • Apr 05

Shareholders Can Be Confident That Adimmune's (TPE:4142) Earnings Are High Quality

Adimmune Corporation ( TPE:4142 ) just reported healthy earnings but the stock price didn't move much. Investors are...
Analysis Article • Mar 01

Is Adimmune (TPE:4142) Using Debt In A Risky Way?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Analysis Article • Jan 07

Introducing Adimmune (TPE:4142), The Stock That Zoomed 158% In The Last Three Years

Adimmune Corporation ( TPE:4142 ) shareholders might be concerned after seeing the share price drop 28% in the last...

CEO Compensation Analysis

How has Steve Chan's remuneration changed compared to Adimmune's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-NT$202m

Dec 31 2025n/an/a

-NT$240m

Sep 30 2025n/an/a

-NT$509m

Jun 30 2025n/an/a

-NT$227m

Mar 31 2025n/an/a

-NT$282m

Dec 31 2024n/an/a

-NT$243m

Sep 30 2024n/an/a

-NT$608m

Jun 30 2024n/an/a

-NT$608m

Mar 31 2024n/an/a

-NT$575m

Dec 31 2023n/an/a

-NT$640m

Sep 30 2023n/an/a

-NT$165m

Jun 30 2023n/an/a

-NT$9m

Mar 31 2023n/an/a

NT$277m

Dec 31 2022NT$24mNT$7m

NT$291m

Sep 30 2022n/an/a

NT$525m

Jun 30 2022n/an/a

NT$267m

Mar 31 2022n/an/a

NT$58m

Dec 31 2021NT$67mNT$7m

NT$43m

Sep 30 2021n/an/a

NT$989m

Jun 30 2021n/an/a

NT$988m

Mar 31 2021n/an/a

NT$1b

Dec 31 2020NT$31mNT$7m

NT$1b

Compensation vs Market: Insufficient data to establish whether Steve's total compensation is reasonable compared to companies of similar size in the TW market.

Compensation vs Earnings: Steve's compensation has been consistent with company performance over the past year.

CEO

Steve Chan

18yrs
Tenure
NT$24,039,000
Compensation

Mr. Chi-Hsien Chan, also known as Steve, has been Chairman of Adimmune Corporation since 2008 and has been its Director and Chief Executive Officer since July 01, 2008. Mr. Chan holds position of Chairman...

Leadership Team

NamePositionTenureCompensationOwnership
Chi-Hsien Chan
CEO & Chairman18yrsNT$24.04mno data
Chin-Chuan Chang
COO and VP of R&D11.7yrsNT$5.34mno data
Chin-I Chiu
Vice President of Quality Assurance Departmentno dataNT$5.13mno data
Li-Ya Tang
Director of Administration Center10.9yrsno datano data
Fei Pan
Chief Legal Officer & General Counsel14.3yrsNT$5.25m0.033%
NT$ 2.3m
Zhe Wei Zhang
Executive Vice GM1.5yrsno data0.013%
NT$ 881.8k
Chih-Hsiang Leng
Head of R&D Division7.3yrsno datano data
Yuan Hou Yan
Deputy Chief Operating Officerno datano datano data
Yue Peng Hong
Deputy Chief Operating Officerno datano datano data
Cheng Liu Churg
Acting R&D Officer1.3yrsno datano data
10.9yrs
Average Tenure

Experienced Management: 4142's management team is seasoned and experienced (10.9 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Chi-Hsien Chan
CEO & Chairman18yrsNT$24.04mno data
Jung-Chin Lin
Director7.1yrsNT$100.00kno data
Shyang Yang Feng
Member of Supervisory Boardno datano datano data
Ming Liang Guo
Member of Supervisory Boardno datano datano data
Chi-Heng Lin
Director17.8yrsNT$100.00k0.0012%
NT$ 83.0k
Mei-Hsing Tseng
Director9.1yrsNT$87.00kno data
Hsiao-Po Hsu
Independent Director14.9yrsNT$970.00kno data
Yung-Sheng Hsu
Independent Director6.1yrsNT$848.00kno data
Mei-Ling Hsiao
Independent Director2.1yrsno datano data
Zhong Rong Lin
Directorno datano datano data
Pei-Chun Hung
Independent Directorno datano datano data
Geng Yi Liang
Independent Directorno datano datano data
9.1yrs
Average Tenure

Experienced Board: 4142's board of directors are considered experienced (9.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/31 16:55
End of Day Share Price 2026/07/31 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Adimmune Corporation is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jianzheng WuCapital Securities Corporation
Hengyu FuMasterlink Securities Investment Advisory
Yijun ChenSinoPac Securities Investment Service